Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Equibles does not estimate personal net worth.
Get an email with a short summary when Emergent BioSolutions Inc. publishes a filing, an earnings call transcript or a press release.
Get EBS alertsRich Lindahl is recorded as CFO at Emergent BioSolutions Inc. (EBS). Rich Lindahl has spoken on 26 earnings calls across 1 company, most recently for Emergent BioSolutions Inc. on August 5, 2026. Emergent BioSolutions Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Emergent BioSolutions Inc. includes Daniel J. Abdun-Nabi (CEO, COO and Board Member), Joseph C. Papa (CEO and Board Member), Joseph Papa (CEO and Board Member) and 7 others.
“We delivered a strong second quarter and first half of 2026, with revenue and adjusted EBITDA exceeding both our internal expectations and the analyst consensus.”
“We started fiscal year 2026 with a strong first quarter, with revenue exceeding the top end of our guidance. We've also advanced key strategic priorities and improved our cash and liquidity position versus the prior year.”
“We're excited to share the strong progress we made in 2025 and the continued momentum we're carrying into 2020 since. 2025 was a year of meaningful advancement for Emergent, one where our transition from stabilization to turnaround gained real traction.”
“As Joe has just highlighted, we are off to a strong start in 2025 as we continue to make progress on our multiyear transformation plan. We delivered first quarter revenue in line with our guidance, enhanced our cash position and reduced our net leverage ratio.”
“As Joe has just discussed coming out of the third quarter, our significant progress against our operational and financial priorities is enabling us to transition from the stabilization phase to the turnaround phase.”
Drug Manufacturers - Specialty & Generic · Healthcare
CFO